New pill tested to control advanced lung cancer
NCT ID NCT07231068
Summary
This study is testing a new oral medication called Dositinib for adults with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The main goals are to find a safe and effective dose and to see how well the drug controls the cancer. The study is in two parts: first to find the right dose, and then to test that dose in more people.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
-
Henan Provincial Cancer Hospital
RECRUITINGZhengzhou, China
-
Henan Provincial People's Hospital
RECRUITINGZhengzhou, China
-
Peking Union Medical College Hospital
WITHDRAWNBeijing, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, China
Conditions
Explore the condition pages connected to this study.